UBS downgraded CureVac (CVAC) to Neutral from Buy with a price target of $5.50, down from $12. BioNTech (BNTX) announced the acquisition of CureVac for $5.46 per share, or a total equity value of $1.25B, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVAC: